Non-nucleoside inhibitors of herpesviruses

Reviews in Medical Virology

Volumn 12, Issue 3, 2002, Pages 167-178

  Wathen, Michael W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,6 NAPHTHYRIDINE DERIVATIVE; 4 OXODIHYDROQUINOLINE DERIVATIVE; ACICLOVIR; ANTIVIRUS AGENT; BENZIMIDAVIR; CIDOFOVIR; DEOXYGUANOSINE; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; GW 273175X; NUCLEOSIDE ANALOG; PENCICLOVIR; PHENYLENEDIAMINE DERIVATIVE; PNU 145185; PNU 181128; PNU 183792; PNU 26370; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPIROCYCLOPROPYLOXAZOLONE; SULFONAMIDE; T 0902611; THIENO[2,3 D]IOXAZINONE; TOMEGLOVIR; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR;

BIOAVAILABILITY; CLINICAL TRIAL; CYTOMEGALOVIRUS; DNA CLEAVAGE; DRUG MECHANISM; DRUG POTENCY; HERPES SIMPLEX; HERPES VIRUS; HUMAN; IMMUNE DEFICIENCY; NONHUMAN; REVIEW;

ANTIVIRAL AGENTS; DNA-DIRECTED DNA POLYMERASE; ENZYME INHIBITORS; HERPES SIMPLEX; HERPESVIRIDAE; HUMANS; PROTEASE INHIBITORS; PROTEIN KINASE INHIBITORS;

EID: 0036093153     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.354     Document Type: Review

References (86)

1. Human herpesvirus 6
2. Human herpesvirus 7
3. Epstein-Barr virus infection
4. Herpes simplex virus latency and nucleoside analogues
5. Herpesviruses and AIDS
6. Viral infections after renal transplantation
7. Herpes simplex viruses
8. Post-transplant lymphoproliferative disease in children
9. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
10. Human cytomegalovirus: Challenges opportunities and new drug development
11. Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma: Case-control and historical cohort studies
12. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients
13. Herpes zoster in older adults
14. Herpes zoster: Focus on treatment in older adults
15. Ganciclovir
16. Drugs for cytomegalovirus: New ways of presenting old drugs and some really new drugs
17. Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients
18. Current and potential therapies for the treatment of herpesvirus infections
19. Foscarnet: A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections
20. Novel agents for the treatment of human cytomegalovirus infection
21. Recent strategies in the development of new human cytomegalovirus inhibitors
22. Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase
23. Development of HIV protease inhibitors: A survey
24. Structure-based discovery of tipranavir disodium (PNU-140690E): A potent, orally bioavailable, nonpeptidic HIV protease inhibitor
25. Targeting the HIV-protease in AIDS therapy: A current clinical perspective
26. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles
27. Novel non-nucleosidic inhibitors of cytomegalovirus - Antiviral activity in vitro
28. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products
29. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56
30. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product
31. A phase I trial evaluating the tolerability and pharmacokinetics of 1263W94 following single oral administration of escalating doses in normal healthy volunteers
32. Mapping of a mutation in human cytomegalovirus resistant to 1263W94
33. 1263W94 inhibits phosphorylation of proteins in human cytomegalovirus infected MRC5 cells
34. Structure-activity relationships of acyloxyamidine cytomegalovirus dNA polymerase inhibitors
35. Naphthalene carboxamides as inhibitors of human cytomegalovirus DNA polymerase
36. Broad spectrum anti-herpesvirus cell culture activity of novel 4-hydroxyquinolines which target the viral polymerase
37. Selective inhibition of herpesvirus polymerases by novel 4-hydroxyquinolines
38. Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses
39. Broad-spectrum anti-herpes activity by 4-hydroxyquinolines. A novel class of herpesvirus polymerase inhibitors
40. Broad-spectrum anti-herpes activity of 4-hydroxyquinoline-3-carboxamides, a novel class of herpesvirus polymerase inhibitors
41. Evaluation of a 4-oxo-dihydroquinoline class of compounds as novel inhibitors of Epstein-Barr virus and human herpesvirus-8
42. Amino acid changes within the herpesvirus DNA polymerase confer resistance to 4-hydroxyquinilines, a novel class of herpesvirus antivirals
43. Mechanism of antiviral action of BAY 38-4766 - A novel nonnucleosidic inhibitor of human cytomegalovirus replication
44. Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir
45. Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo
46. Safety, tolerability, and pharmacokinetics of single oral doses of BAY 38-4766 - A novel, nonnucleosidic inhibitor of human cytomegalovirus (HCMV) replication - In healthy male subjects
47. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl) benzimidazoles
48. Design, synthesis, and antiviral evaluation of 2-chloro-5,6-dihalo-10-β-Dribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections
49. Synthesis and evaluation of a series of 1H-benzimidazole pyranosides as anti-human cytomegalovirus agents
50. Antiviral activity and mechanism of action of 1263W94, a benzimidazole riboside inhibitor of human cytomegalovirus
51. Benzimidazoles for the treatment of human cytomegalovirus
52. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: Novel antiviral mechanism of 5,6-dichloro-2-(isopropylamino)-1-β-ribofuranosyl-1H-benzimidazole
53. In vivo anti-CMV activity and safety of oral 1263W94 in HIV-infected subjects with asymptomatic CMV shedding
54. The herpes simplex virus 1 gene encoding a protease also contains within its coding domain the gene encoding the more abundant substrate
55. A herpesvirus maturational protease assemblin: Identification of its gene, putative active site domain, and cleavage site
56. The size and symmetry of B capsids of herpes simplex virus type 1 are determined by the gene products of the UL26 open reading frame
57. The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth
58. Protease-deficient herpes simplex virus protects mice from lethal herpesvirus infection
59. Identification and characterization of a herpes simplex virus gene product required for encapsidation of virus DNA
60. Cloning and sequence analysis of murine cytomegalovirus protease and capsid assembly protein genes
61. Herpesvirus proteinase: Site-directed mutagenesis used to study maturational, release, and inactivation cleavage sites of precursor and to identify a possible catalytic site serine and histidine
62. Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad
63. Unique fold and active site in cytomegalovirus protease
64. Three-dimensional structure of human cytomegalovirus protease
65. A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease
66. Molecular mechanism for dimerization to regulate the catalytic activity of human cytomegalovirus protease
67. Herpesvirus proteases: Targets for novel antiviral drugs
68. The herpesvirus proteases as targets for antiviral chemotherapy
69. Inhibition of HSV-1 protease by benzoxazinones
70. Potent selective thienoxazinone inhibitors of herpes proteases
71. Inhibition of herpes proteases and antiviral activity of 2-substituted thieno[2,3-d]oxazinones
72. Novel, selective mechanism-based inhibitors of the herpes proteases
73. Inhibition of human cytomegalovirus protease by enedione derivatives of thieno[2,3-d]oxazinones through a novel dual acylation/alkylation mechanism
74. Recent advances in antiviral research: Identification of inhibitors of the herpesvirus proteases
75. SAR studies of a novel series human cytomegalovirus primase inhibitors
76. Design of T0902611: A novel non-nucleoside inhibitor of human cytomegalovirus replication
77. Activity of CADA analogues against human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV)
78. CADA compounds: Novel chemotherapeutic agents for the human cytomegalovirus (HCMV)
79. Activity of CADA (cyclotriazadisulfonamide) derivatives against herpesviruses
80. Antiviral properties of a series of 1,6-napthyridine and 7,8-dihydroisoquinoline derivatives exhibiting potent activity against human cytomegalovirus
81. Discovery of 1,6-naphthyridines as a novel class of potent and selective human cytomegalovirus inhibitors
82. Isoquinoline-6-carboxamides as potent and selective anti-human cothmegalovirus (HCMV) inhibitors
83. Substituted 1,6-naphthyridines as human cytomegalovirus inhibitors: Conformational requirements
84. Potent novel thioureas as inhibitors of human cytomegalovirus